KRAS and colorectal carcinoma: Cologuard, a stool DNA test approved by FDA for CRC screening in 2014, employs multiple biomarkers including two methylated genes (BMP3 and NDRG4), 7 KRAS mutation sites and an immunochemical assay for human hemoglobin.